BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

570 related articles for article (PubMed ID: 14633783)

  • 21. Front-line therapy in polycythemia vera and essential thrombocythemia.
    Barbui T; Finazzi MC; Finazzi G
    Blood Rev; 2012 Sep; 26(5):205-11. PubMed ID: 22784966
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Myeloproliferative Neoplasms: A Contemporary Review.
    Tefferi A; Pardanani A
    JAMA Oncol; 2015 Apr; 1(1):97-105. PubMed ID: 26182311
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Philadelphia chromosome negative chronic myeloproliferative disorders: a practical overview.
    Tefferi A
    Mayo Clin Proc; 1998 Dec; 73(12):1177-84. PubMed ID: 9868417
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
    Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W
    Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular detection of c-mpl thrombopoietin receptor gene expression in chronic myeloproliferative disorders.
    Duensing S; Duensing A; Meran JG; Kreft A; Büsche G; Ganser A; Georgii A
    Mol Pathol; 1999 Jun; 52(3):146-50. PubMed ID: 10621836
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Polycythemia vera and essential thrombocythemia: 2013 update on diagnosis, risk-stratification, and management.
    Tefferi A
    Am J Hematol; 2013 Jun; 88(6):507-16. PubMed ID: 23695894
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Polycythemia vera: scientific advances and current practice.
    Tefferi A; Spivak JL
    Semin Hematol; 2005 Oct; 42(4):206-20. PubMed ID: 16210034
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapeutic dilemmas: balancing the risks of bleeding, thrombosis, and leukemic transformation in myeloproliferative disorders (MPD).
    Murphy S
    Thromb Haemost; 1997 Jul; 78(1):622-6. PubMed ID: 9198227
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aberrant expression of transforming growth factor beta-1 (TGF beta-1) per se does not discriminate fibrotic from non-fibrotic chronic myeloproliferative disorders.
    Bock O; Loch G; Schade U; von Wasielewski R; Schlué J; Kreipe H
    J Pathol; 2005 Apr; 205(5):548-57. PubMed ID: 15726648
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A novel thrombopoietin signaling defect in polycythemia vera platelets.
    Moliterno AR; Siebel KE; Sun AY; Hankins WD; Spivak JL
    Stem Cells; 1998; 16 Suppl 2():185-92. PubMed ID: 11012190
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chronic myeloproliferative diseases on a pathologist's desk--a dilemma of distinct entities versus a clinico-pathologic continuum. A descriptive study based on a material from the Polish population.
    Rudzki Z; Papla B; Stachura J
    Pol J Pathol; 2004; 55(1):13-23. PubMed ID: 15195702
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Application of PRV-1 mRNA expression level and JAK2V617F mutation for the differentiating between polycytemia vera and secondary erythrocytosis and assessment of treatment by interferon or hydroxyurea.
    Tutaeva V; Misurin AV; Michiels JJ; Rozenberg JM; Sokolova MA; Ivanova VL; Kolosheinova TI; Manakova TE; Levina AA; Semenova EA; Khoroshko ND
    Hematology; 2007 Dec; 12(6):473-9. PubMed ID: 17852451
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Myeloproliferative neoplasms and pregnancy: Overview and practice recommendations.
    Gangat N; Tefferi A
    Am J Hematol; 2021 Mar; 96(3):354-366. PubMed ID: 33296529
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Incidence and clinical risk factors for bleeding and thrombotic complications in myeloproliferative disorders. A retrospective analysis of 260 patients.
    Wehmeier A; Daum I; Jamin H; Schneider W
    Ann Hematol; 1991 Aug; 63(2):101-6. PubMed ID: 1912029
    [TBL] [Abstract][Full Text] [Related]  

  • 35. WHO bone marrow features and European clinical, molecular, and pathological (ECMP) criteria for the diagnosis of myeloproliferative disorders.
    Michiels JJ; De Raeve H; Hebeda K; Lam KH; Berneman Z; Schroyens W; Schwarz J
    Leuk Res; 2007 Aug; 31(8):1031-8. PubMed ID: 17367853
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Thrombopoietin receptor (Mpl) expression by megakaryocytes in myeloproliferative disorders.
    Bock O; Schlué J; Mengel M; Büsche G; Serinsöz E; Kreipe H
    J Pathol; 2004 May; 203(1):609-15. PubMed ID: 15095485
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A prospective analysis of thrombotic events in the European collaboration study on low-dose aspirin in polycythemia (ECLAP).
    Finazzi G;
    Pathol Biol (Paris); 2004 Jun; 52(5):285-8. PubMed ID: 15217715
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Annual Clinical Updates in Hematological Malignancies: a continuing medical education series: polycythemia vera and essential thrombocythemia: 2011 update on diagnosis, risk-stratification, and management.
    Tefferi A
    Am J Hematol; 2011 Mar; 86(3):292-301. PubMed ID: 21351120
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Essential thrombocythemia. Contribution of the V617F JAK2 mutation to the pathophysiology, diagnosis and outcome].
    Brière J
    Bull Acad Natl Med; 2007 Mar; 191(3):535-48. PubMed ID: 18072652
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Low-risk polycythemia vera and essential thrombocythemia: management considerations and future directions.
    Goulart H; Mascarenhas J; Tremblay D
    Ann Hematol; 2022 May; 101(5):935-951. PubMed ID: 35344066
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.